Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Minus Medco Sets Ambitious Margin Benchmark: 82% On Pure Rx

Executive Summary

Merck's first post-Medco benchmark for the investment community is a reinvigorated pure pharma gross profit margin of 82%

You may also be interested in...



Medco IPO Delay: Merck Trades Gross Margin For Cloudy Rebate Calculations

Merck's gross margins would be about five percentage points higher if the company excluded copayments for Medco-managed prescriptions from its revenue line

Medco IPO Delay: Merck Trades Gross Margin For Cloudy Rebate Calculations

Merck's gross margins would be about five percentage points higher if the company excluded copayments for Medco-managed prescriptions from its revenue line

Zocor To Get Special Medco Attention: Market Share Protections Set In IPO

Merck's Zocor protection program for the spin-off of MedcoHealth Solutions includes an incentive for Medco to keep the cholesterol agent at a market share level tied to its 2001 position

Related Content

UsernamePublicRestriction

Register

PS039717

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel